Glial Cells in Glaucoma: Friends, Foes, and Potential Therapeutic Targets
Mariana Y Garcia-Bermudez, Kristine K Freude, Zaynab A Mouhammad, Peter van Wijngaarden, Keith K Martin, Miriam Kolko
FRONTIERS IN NEUROLOGY | FRONTIERS MEDIA SA | Published : 2021
Glaucoma is the second leading cause of blindness worldwide, affecting ~80 million people by 2020 (1, 2). The condition is characterized by a progressive loss of retinal ganglion cells (RGCs) and their axons accompanied by visual field loss. The underlying pathophysiology of glaucoma remains elusive. Glaucoma is recognized as a multifactorial disease, and lowering intraocular pressure (IOP) is the only treatment that has been shown to slow the progression of the condition. However, a significant number of glaucoma patients continue to go blind despite intraocular pressure-lowering treatment (2). Thus, the need for alternative treatment strategies is indisputable. Accumulating evidence sugges..View full abstract
The study was supported by the Velux Foundation, Denmark; Bagenkop-Nielsens Eye-Foundation, Denmark and the Horslev Foundation, Denmark.